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   Neocarzinpstatin．（NC S） was adrpini．strated to 14 patients with advan．ced carcinoma of the prostate
（T3 or T4 in TNM system） either alone or in combinatiop with diethylstilbestrol （DES）． The’infusion
catheter was inserted into the cornmon iliac artery following the Seldinger’s method and 2 to 8 mg
of NCS in 20 ml of physiolQgical saline solution was injected under the obstruction of the external
iliac artery fiow by dppressing bilateral femoral arteries with fingers． NCS was given once a week
and we performed the course for 3 weeks．
   Objective response to therapy was considered as complete （CR） if no tumor was demonstrated
urethrography or ultrasonography and if the restoration of．the elevated serum phosphatase levels
to normal was seen． Objective response was considered’as partial （PR） if a 500／， or more reduction
in primary tumor was demonstrated and if increase of elevated serum phosphatase level was seen．
Subjective response was considered as complete （CR） when significant improvement in urinary dis一
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turbance， pain and performance status were seen， and PR when reduction in symptoms were seen・
  Histological response was exarnined following the Shimosato’s classification （Table 2）． Grade
3 and 4 was classified to CR， Grade 2 was PR， Grade O and 1 was no response．
  Response rate （CR十PR） was more than 800／． in subjective findings， total acid．phesphatase and
prostatic acid phosphatase． Response rate by urethrography and ultrasonography was 500／o， 610／o
respectively． No different findings were seen in the two groups with DES and without DES．
  Histological response rate was 670／． and no difference was seen in the two groups・
  Side effects were minimal and vanished soon after protocol．
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ったが，Grade O～1を無効（NR）， Grade H a～II b
をPR， Grade III－VIをCRとした警
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TNM i T314 T4i8 NO；2
Histological findings ：
 well differentiated 9
 moderate differentiated 3




 performance status （＞2）
Objective findigs ：
 total acid phospatase
 prostatic acid phosphatase
 alkalne phosphatase
Tratment ：
 NCS 2mgx3 1
       4mgx3 12


























O． Characteristic changes are not seen．
1 ． Characteristic changes are noted ln tumor ceils but tumor structures have not been
    destroyed （there is no defect’in tumor nests resulted from lysis of individual tumor
    celis．）
II． ln adition to characteristic cellular changes， tumor structures have been destroyed
    as a result ef dLsappearance of tumor cells． However， variable number of ‘tviable
    cells” still reMain．
    a． Destruction of tumor structures is of mild degree， L．e．， ‘‘viable tumor ceils” are
       frequently observed．
    b． Destruction of tumor structures is of severe degree， that is， ‘‘viable tumor cel］s”
       are few in number．
III， Markedly altered， presumably non－viable tumor cells are present singly or in small
    ciusters and ‘‘vLable ce“s” are hardly seen．
IXL No tumor cells remain in any of sections （local cure）．
    a． ExtenSEve areas ef coagulatton necrosis’ are presented．
    b， Granulatton’tissue． with or wEthout small foct．of necrosis． including keratotic
       debris reMains．
    c． Only clcatnx is observed
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Table 8． Clinical effects
NO， of With DES Without DES Tota［ Respon＄ Rate
Patients CR PR NR CR PR NR CR PR NR CR十PR（O／．）
Objective
 Total acid phosphatase
























































Table 4． Histological effects



































































果判定をおこなうとGrade VI O例，’Grade III 2
例，Grade II a～Il b 6例， Grade O～14例であり，
CR 2例（16．6％）， PR 6例（50．O％）， NR 4例
』（33．3％）であった．
 DES併用群とNGS単独群の比較では， DES併用
群でCR 2例， PR 3例， NR・2例， NCS単独群で
はGR O例， PR 3．例， NR 2例である．初回治療群
ではCR 2例， PR 4例， NR．3例で，再燃例では
CR O例， PR 2例， NR 1例である．組織学的分類
では，分化型CR 2例， PR 3例， NR 2例，中等
度分化型CR O例， PR 1例，．NR 2例，未分化型で
CR O例， PR 2例， NR O例であった．またsmall
acinal typeはCR 1例， PR 3例， NR 1例， large
acinal typeではCR O例， PR 2例， NR O例，
cribrif｛）rmでは（】R 1例， PR O例， NR 2例であ
っアこ．
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Table 5． Histological findings， treatment and histological effects
Case Age T N M
No．
Pathologicai FLndingsDose of NCS Tota［ Doses PathoL Effect




































Well diff． Smali acinal
Well diff． Small acinal
Well diff． Small acinai
Well diff， Large acinal
Well diff， Small acinal
Well dEff． Smail acinal
Poorly diff，
Moderate dtff．






























12 80 41113 78 41114 81 4Xl
Moderate diff． Small acinal
Well dEff， Large acinal

































 治療前の組織所見は分化型のsmall acinal typeで






 治療前の組織所見は高分化型のlarge acinal type
でpapillary infoldingな発育が見られるがNCS 4 mg
3回動注，DES 109投与後の病理組織所見（Fig・5）
では組織構築の破壊が認められ癌細胞も変化している





















Fig 1 Schowmg Grade III effect （CR） （A） Prebiopsy （B） Postbiopsy












Fig 3． Schowmg Grade 1 effect （NR） （A） Prebiopsy （B） Postbiopsy
審9
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